<DOC>
	<DOCNO>NCT02161315</DOCNO>
	<brief_summary>Steroid Aromatase Inhibitors Non-Steroid Aromatase Inhibitors Late Stage Breast Cancer recommend scheme National Comprehensive Cancer Network ( NCCN ) guideline . In past controlled clinical trial small sample .</brief_summary>
	<brief_title>Steroid Aromatase Inhibitors Versus Progestogens nSAID-resistanced Late Stage Breast Cancer</brief_title>
	<detailed_description>A Randomized Study Steroid Aromatase Inhibitors Versus Progestogens Non-Steroid Aromatase Inhibitor-resistanced Late Stage Breast Cancer.The primary endpoint study progression free survival ( PFS ) . The secondary endpoint overall response rate ( ORR ) , overall survival ( OS ) safety .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Progestins</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<criteria>1 . Patients must postmenopausal woman 2 . Patients must diagnose advanced breast cancer imageologyï¼Œcytology histopathology 3 . Immunohistochemistry show ER and/or PR positive 4 . Patients ECOG score must 02 5 . Drug resistant NonSteroid Aromatase Inhibitors 1 . Not suitable endocrine therapy 2 . Have receive standard Steroid Aromatase Inhibitors treatment 3 . Severe hepatic dysfunction</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>SAID , Progestogens , nSAID-resistanced , LSBC</keyword>
</DOC>